Cargando…

Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices

BACKGROUND: Dysregulation of both cellular and humoral immune responses is central in systemic lupus erythematosus (SLE) pathogenetic mechanisms. Proinflammatory cytokines, such as interleukin 23 (IL23), and their roles in promoting such dysregulation have recently been highly considered. This resea...

Descripción completa

Detalles Bibliográficos
Autores principales: Haroon, Maysa M, Hegazy, Gehan A, Hassanien, Mohammed A, Shaker, Olfat, Hussein, Wafaa H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868139/
https://www.ncbi.nlm.nih.gov/pubmed/36698375
http://dx.doi.org/10.2147/BTT.S389021
_version_ 1784876468839383040
author Haroon, Maysa M
Hegazy, Gehan A
Hassanien, Mohammed A
Shaker, Olfat
Hussein, Wafaa H
author_facet Haroon, Maysa M
Hegazy, Gehan A
Hassanien, Mohammed A
Shaker, Olfat
Hussein, Wafaa H
author_sort Haroon, Maysa M
collection PubMed
description BACKGROUND: Dysregulation of both cellular and humoral immune responses is central in systemic lupus erythematosus (SLE) pathogenetic mechanisms. Proinflammatory cytokines, such as interleukin 23 (IL23), and their roles in promoting such dysregulation have recently been highly considered. This research compared IL23 serum levels in 85 Egyptian SLE patients and 85 healthy controls. Then, IL23 level was correlated to various SLE disease parameters, disease activity, and damage indices. RESULTS: IL23 serum levels were significantly elevated in SLE patients versus healthy individuals. Furthermore, IL23 levels were positively correlated with SLE disease activity index (SLEDAI) and were positively correlated with arthritis, seizures, consumption of complements (C3, C4), and with parameters of nephritis (hematuria, pyuria, casts, and proteinuria). A positive correlation was also found between IL23 levels and oral prednisolone dose. CONCLUSION: IL23 has higher levels in the serum of SLE patients, and is correlated to activity of the disease, especially lupus nephritis. Further researchis needed to explore its exact role in SLE pathogenesis and whether it can be considered a potential biomarker or therapeutic target in SLE.
format Online
Article
Text
id pubmed-9868139
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-98681392023-01-24 Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices Haroon, Maysa M Hegazy, Gehan A Hassanien, Mohammed A Shaker, Olfat Hussein, Wafaa H Biologics Original Research BACKGROUND: Dysregulation of both cellular and humoral immune responses is central in systemic lupus erythematosus (SLE) pathogenetic mechanisms. Proinflammatory cytokines, such as interleukin 23 (IL23), and their roles in promoting such dysregulation have recently been highly considered. This research compared IL23 serum levels in 85 Egyptian SLE patients and 85 healthy controls. Then, IL23 level was correlated to various SLE disease parameters, disease activity, and damage indices. RESULTS: IL23 serum levels were significantly elevated in SLE patients versus healthy individuals. Furthermore, IL23 levels were positively correlated with SLE disease activity index (SLEDAI) and were positively correlated with arthritis, seizures, consumption of complements (C3, C4), and with parameters of nephritis (hematuria, pyuria, casts, and proteinuria). A positive correlation was also found between IL23 levels and oral prednisolone dose. CONCLUSION: IL23 has higher levels in the serum of SLE patients, and is correlated to activity of the disease, especially lupus nephritis. Further researchis needed to explore its exact role in SLE pathogenesis and whether it can be considered a potential biomarker or therapeutic target in SLE. Dove 2023-01-18 /pmc/articles/PMC9868139/ /pubmed/36698375 http://dx.doi.org/10.2147/BTT.S389021 Text en © 2023 Haroon et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Haroon, Maysa M
Hegazy, Gehan A
Hassanien, Mohammed A
Shaker, Olfat
Hussein, Wafaa H
Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices
title Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices
title_full Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices
title_fullStr Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices
title_full_unstemmed Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices
title_short Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices
title_sort significance of interleukin 23 in systemic lupus patients: relation to disease activity and damage indices
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868139/
https://www.ncbi.nlm.nih.gov/pubmed/36698375
http://dx.doi.org/10.2147/BTT.S389021
work_keys_str_mv AT haroonmaysam significanceofinterleukin23insystemiclupuspatientsrelationtodiseaseactivityanddamageindices
AT hegazygehana significanceofinterleukin23insystemiclupuspatientsrelationtodiseaseactivityanddamageindices
AT hassanienmohammeda significanceofinterleukin23insystemiclupuspatientsrelationtodiseaseactivityanddamageindices
AT shakerolfat significanceofinterleukin23insystemiclupuspatientsrelationtodiseaseactivityanddamageindices
AT husseinwafaah significanceofinterleukin23insystemiclupuspatientsrelationtodiseaseactivityanddamageindices